This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, F. R. Articles by Heppner, G. H. Search for Related Content PubMed PubMed Citation Articles by Miller, F. R. Articles by Heppner, G. H.

Preferential Growth of Mammary Tumors in Intact Mammary Fatpads¹

Department of Immunology, Michigan Cancer Foundation, Detroit, Michigan 48201 [F. R. M., G. H. H.] and Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77025 [D. M.]

Four transplantable mammary tumors, three (66, 410, and 168cl) isolated from a spontaneously occurring strain BALB/cfC3H mammary tumor and one (D2) arising from a BALB/c hyperplastic alveolar nodule were found to grow better in mammary fatpads than at s.c. sites. Furthermore, tumor growth was better (p < 0.05) in intact mammary glands than in cleared mammary fatpads for the D2, 410, and 66 tumors (168cl was not tested). The role of immunity in these differences was investigated using the highly immunogenic 410 tumor. Tumor 410 induced equally effective immunity to subsequent challenge whether it was implanted s.c. or in intact fatpads. Furthermore, in immunized animals, Tumor 410 was rejected equally well when the challenge site was intact fatpad as when s.c. Similarly, Tumor 410 induced immunity after implantation into cleared fatpads and, in immunized animals, was rejected when the challenge site was the cleared fatpad. We thus found no evidence that the mammary fatpad is immunologically privlleged, as compared to the s.c. site, with respect to tumor transplantation antigens.

¹ This work was supported by USPHS Grants CA 22453, CA 27437, and CA 28366 and by a grant from the Concern Foundation.

² To whom requests for reprints should be addressed, at the Department of Immunology, Michigan Cancer Foundation, 110 E. Warren Ave., Detroit, Mich. 48201.

Received 4/20/81. Accepted 6/23/81.

This article has been cited by other articles:

				R. Munoz, S. Man, Y. Shaked, C. R. Lee, J. Wong, G. Francia, and R. S. Kerbel Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. Cancer Res., April 1, 2006; 66(7): 3386 - 3391. [Abstract] [Full Text] [PDF]

				A. K. Man, L. J. T. Young, J. A. Tynan, J. Lesperance, M. Egeblad, Z. Werb, C. A. Hauser, W. J. Muller, R. D. Cardiff, and R. G. Oshima Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors Mol. Cell. Biol., December 1, 2003; 23(23): 8614 - 8625. [Abstract] [Full Text] [PDF]

				K. L. Schmeichel and M. J. Bissell Modeling tissue-specific signaling and organ function in three dimensions J. Cell Sci., June 15, 2003; 116(12): 2377 - 2388. [Abstract] [Full Text] [PDF]

				B. Elenbaas, L. Spirio, F. Koerner, M. D. Fleming, D. B. Zimonjic, J. L. Donaher, N. C. Popescu, W. C. Hahn, and R. A. Weinberg Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells Genes & Dev., January 1, 2001; 15(1): 50 - 65. [Abstract] [Full Text]